Eirini I Rigopoulou

List of Publications by Year
in descending order

97	3,445	117453	161609
papers	citations	34 h-index	54 g-index

99	99	99	3371
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Impact on followâ€up strategies in patients with primary sclerosing cholangitis. Liver International, 2023, 43, 127-138.	1.9	15
2	The changing epidemiology of hepatitis B in Greece. Annals of Gastroenterology, 2021, 34, 431-437.	0.4	0
3	Current Trends and Characteristics of Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases. Cancers, 2021, 13, 1023.	1.7	20
4	Alcoholic liver disease and autoimmune hepatitis: Sometimes a closer look under the surface is needed. European Journal of Internal Medicine, 2021, 85, 86-91.	1.0	13
5	p38 mitogenâ€activated protein kinase impairment of innate immune cells is a characteristic feature of HBeAgâ€negative chronic hepatitis B. Journal of Viral Hepatitis, 2020, 27, 52-60.	1.0	0
6	Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAgâ€negative chronic hepatitis B. Journal of Viral Hepatitis, 2020, 27, 118-126.	1.0	38
7	Diagnostic and clinical significance of antigen-specific pancreatic antibodies in inflammatory bowel diseases: A meta-analysis. World Journal of Gastroenterology, 2020, 26, 246-265.	1.4	5
8	Autoimmune hepatitis in patients with multiple sclerosis: The role of immunomodulatory treatment. Clinics and Research in Hepatology and Gastroenterology, 2019, 43, e25-e32.	0.7	10
9	Efficient management of secondary haemophagocytic lymphohistiocytosis with intravenous steroids and Î³-immunoglobulin infusions. World Journal of Clinical Cases, 2019, 7, 3394-3406.	0.3	9
10	DARING-B: Discontinuation of Effective Entecavir or Tenofovir Disoproxil Fumarate Long-Term Therapy before HBsAg Loss in Non-Cirrhotic HBeAg-Negative Chronic Hepatitis B. Antiviral Therapy, 2018, 23, 677-685.	0.6	68
11	Geoepidemiology, clinical manifestations and outcome of primary biliary cholangitis in Greece. European Journal of Internal Medicine, 2017, 42, 81-88.	1.0	37
12	Immune responses against Helicobacter pylori-specific antigens differentiate relapsing remitting from secondary progressive multiple sclerosis. Scientific Reports, 2017, 7, 7929.	1.6	20
13	Polymorphisms of IL12RB2 May Affect the Natural History of Primary Biliary Cholangitis: A Single Centre Study. Journal of Immunology Research, 2017, 2017, 1-5.	0.9	5
14	Ascites in a patient with episodic angio-oedema and eosinophilia: thinking outside the box. BMJ Case Reports, 2017, 2017, bcr-2017-219467.	0.2	2
15	PATIENTS WITH HAEMOGLOBINOPATHIES AND CHRONIC HEPATITIS C: A REALLY DIFFICULT TO TREAT POPULATION IN 2016?. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 9, e2017003.	0.5	10
16	Assessment of health related quality of life in polish patients with primary biliary cirrhosis. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 471-479.	0.7	35
17	Infection and Autoimmune Liver Diseases. , 2015, , 839-857.		0
18	Crohn's disease-specific anti-CUZD1 pancreatic antibodies are absent in ruminants with paratuberculosis. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, 384-390.	0.7	4

#	Article	IF	Citations
19	Oxidative stress and antioxidant status in patients with autoimmune liver diseases. Redox Report, 2015, 20, 33-41.	1.4	34
20	Prospective evaluation of <scp>PBC</scp>â€specific healthâ€related quality of life questionnaires in patients with primary sclerosing cholangitis. Liver International, 2015, 35, 1764-1771.	1.9	31
21	Autoimmune hepatitis in patients with chronic HBV and HCV infections: patterns of clinical characteristics, disease progression and outcome. Annals of Hepatology, 2014, 13, 127-135.	0.6	40
22	Is primary biliary cirrhosis rare or common? The truth lies somewhere in between. Liver International, 2014, 34, e165-7.	1.9	3
23	Helicobacter pyloriand autoimmune disease: Cause or bystander. World Journal of Gastroenterology, 2014, 20, 613.	1.4	130
24	Flow Cytometric Detection of p38 MAPK Phosphorylation and Intracellular Cytokine Expression in Peripheral Blood Subpopulations from Patients with Autoimmune Rheumatic Diseases. Journal of Immunology Research, 2014, 2014, 1-13.	0.9	6
25	Hair dyes as a risk for autoimmunity: from systemic lupus erythematosus to primary biliary cirrhosis. Autoimmunity Highlights, 2013, 4, 1-9.	3.9	16
26	Tracing environmental markers of autoimmunity: introducing the infectome. Immunologic Research, 2013, 56, 220-240.	1.3	35
27	Crohnâ€™s disease-specific pancreatic autoantibodies are specifically present in ruminants with paratuberculosis: Implications for the pathogenesis of the human disease. Autoimmunity, 2013, 46, 388-394.	1.2	7
28	Infectome: A platform to trace infectious triggers of autoimmunity. Autoimmunity Reviews, 2013, 12, 726-740.	2.5	94
29	p38 mitogen-activated protein kinase (p38 MAPK)-mediated autoimmunity: Lessons to learn from ANCA vasculitis and pemphigus vulgaris. Autoimmunity Reviews, 2013, 12, 580-590.	2.5	41
30	Potential Roles for Infectious Agents in the Pathophysiology of Primary Biliary Cirrhosis: Whatâ€™s New?. Current Infectious Disease Reports, 2013, 15, 14-24.	1.3	22
31	CUZD1 and Anti-CUZD1 Antibodies as Markers of Cancer and Inflammatory Bowel Diseases. Clinical and Developmental Immunology, 2013, 2013, 1-11.	3.3	12
32	Primary biliary cirrhosis in HBV and HCV patients: Clinical characteristics and outcome. World Journal of Hepatology, 2013, 5, 577.	0.8	17
33	Autoimmune hepatitis in patients with chronic HBV and HCV infections: patterns of clinical characteristics, disease progression and outcome. Annals of Hepatology, 2013, 13, 127-35.	0.6	16
34	Autoantibodies in Autoimmune Pancreatitis. International Journal of Rheumatology, 2012, 2012, 1-8.	0.9	34
35	Sex Differences Associated with Primary Biliary Cirrhosis. Clinical and Developmental Immunology, 2012, 2012, 1-11.	3.3	37
36	Tuberculosis Is Not a Risk Factor for Primary Biliary Cirrhosis: A Review of the Literature. Tuberculosis Research and Treatment, 2012, 2012, 1-10.	0.2	2

#	Article	IF	Citations
37	Asialoglycoprotein receptor (ASGPR) as target autoantigen in liver autoimmunity: Lost and found. Autoimmunity Reviews, 2012, 12, 260-269.	2.5	81
38	Towards systemic sclerosis and away from primary biliary cirrhosis: the case of PTPN22. Autoimmunity Highlights, 2012, 3, 1-9.	3.9	8
39	Popular and unpopular infectious agents linked to primary biliary cirrhosis. Autoimmunity Highlights, 2012, 3, 95-104.	3.9	4
40	Twin studies in autoimmune disease: Genetics, gender and environment. Journal of Autoimmunity, 2012, 38, J156-J169.	3.0	233
41	Diagnostic and clinical utility of antibodies against the nuclear body promyelocytic leukaemia and Sp100 antigens in patients with primary biliary cirrhosis. Clinica Chimica Acta, 2012, 413, 1211-1216.	0.5	48
42	Urinary tract infection as a risk factor for autoimmune liver disease: From bench to bedside. Clinics and Research in Hepatology and Gastroenterology, 2012, 36, 110-121.	0.7	42
43	Reactivation of resolved hepatitis B virus infection after immunosuppression: Is it time to adopt pre-emptive therapy?. Clinics and Research in Hepatology and Gastroenterology, 2012, 36, 84-93.	0.7	18
44	Epstein-Barr Virus as a Trigger of Autoimmune Liver Diseases. Advances in Virology, 2012, 2012, 1-12.	0.5	43
45	Smoking as a risk factor for autoimmune liver disease: what we can learn from primary biliary cirrhosis. Annals of Hepatology, 2012, 11, 7-14.	0.6	36
46	Autoimmunity and Environment: Am I at risk?. Clinical Reviews in Allergy and Immunology, 2012, 42, 199-212.	2.9	60
47	Role for mycobacterial infection in pathogenesis of primary biliary cirrhosis?. World Journal of Gastroenterology, 2012, 18, 4855.	1.4	11
48	Smoking as a risk factor for autoimmune liver disease: what we can learn from primary biliary cirrhosis. Annals of Hepatology, 2012, 11, 7-14.	0.6	20
49	Mycophenolate for the treatment of autoimmune hepatitis: Prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naÂ¨ve patients. Journal of Hepatology, 2011, 55, 636-646.	1.8	163
50	Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn's disease specific-pancreatic autoantibodies. Autoimmunity Reviews, 2011, 11, 143-148.	2.5	59
51	Fetomaternal alloimmunity as a cause of liver disease. Autoimmunity Highlights, 2011, 2, 21-28.	3.9	5
52	Immunopathogenesis of primary biliary cirrhosis: an old wives' tale. Immunity and Ageing, 2011, 8, 12.	1.8	25
53	Primary Biliary Cirrhosis Associated with Systemic Sclerosis: Diagnostic and Clinical Challenges. International Journal of Rheumatology, 2011, 2011, 1-12.	0.9	39
54	Primary Biliary Cirrhosis: Family Stories. Autoimmune Diseases, 2011, 2011, 1-11.	2.7	34

#	Article	IF	Citations
55	Salmonella enteritidisInfection Complicated by Acute Myocarditis: A Case Report and Review of the Literature. Cardiology Research and Practice, 2011, 2011, 1-6.	0.5	11
56	Can mathematical models be useful in clinical hepatology?. Liver International, 2010, 30, 637-638.	1.9	2
57	PBC Triggers in Water Reservoirs, Coal Mining Areas and Waste Disposal Sites: From Newcastle to New York. Disease Markers, 2010, 29, 337-344.	0.6	31
58	Prevalence of occult hepatitis B virus infection in haemodialysis patients from central Greece. World Journal of Gastroenterology, 2010, 16, 225.	1.4	36
59	Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: A new or a complementary diagnostic score?. Digestive and Liver Disease, 2010, 42, 807-812.	0.4	63
60	Prevalence of gastric parietal cell antibodies and intrinsic factor antibodies in primary biliary cirrhosis. Clinica Chimica Acta, 2010, 411, 411-415.	0.5	18
61	PBC triggers in water reservoirs, coal mining areas and waste disposal sites: from Newcastle to New York. Disease Markers, 2010, 29, 337-44.	0.6	26
62	Occult hepatitis B virus infection in patients with autoimmune liver diseases. Liver International, 2009, 29, 434-442.	1.9	47
63	Descriptive epidemiology of chronic hepatitis B by using data from a hepatitis registry in Central Greece. European Journal of Internal Medicine, 2009, 20, 35-43.	1.0	18
64	IgA Anti-b2GPI Antibodies in Patients with Autoimmune Liver Diseases. Journal of Clinical Immunology, 2008, 28, 501-511.	2.0	37
65	Autoimmune hepatitis: Of host and pathogen. Hepatology, 2008, 47, 2147-2148.	3.6	3
66	Bone marrow findings in patients with autoimmune liver diseases. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, e416-21.	1.4	6
67	Molecular diagnostics of primary biliary cirrhosis. Expert Opinion on Medical Diagnostics, 2008, 2, 621-634.	1.6	23
68	Autoimmune hepatitis-specific antibodies against soluble liver antigen and liver cytosol type 1 in patients with chronic viral hepatitis. Journal of Autoimmune Diseases, 2007, 4, 2.	1.0	22
69	Risk factors associated with HCV infection in semi-rural areas of central Greece. European Journal of Internal Medicine, 2007, 18, 48-55.	1.0	17
70	Anti-mitochondrial antibody immunofluorescent titres correlate with the number and intensity of immunoblot-detected mitochondrial bands in patients with primary biliary cirrhosis. Clinica Chimica Acta, 2007, 380, 118-121.	0.5	34
71	Viral/self-mimicry and immunological cross-reactivity as a trigger of hepatic C virus associated autoimmune diabetes. Diabetes Research and Clinical Practice, 2007, 77, 155-156.	1.1	20
72	Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis. Hepatology, 2007, 45, 1583-1583.	3.6	51

#	Article	IF	Citations
73	Development of antimitochondrial antibodies in patients with autoimmune hepatitis: Art of facts or an artifact?. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 454-455.	1.4	21
74	Primary biliary cirrhosis and Henoch?Schonlein purpura: report of two cases and review of the literature. Liver International, 2007, 27, 280-283.	1.9	17
75	Antimitochondrial antibodies of immunoglobulin G3 subclass are associated with a more severe disease course in primary biliary cirrhosis. Liver International, 2007, 27, 1226-1231.	1.9	56
76	Direct evidence for immunomodulatory properties of ribavirin on T-cell reactivity to hepatitis C virus. Antiviral Research, 2007, 75, 36-42.	1.9	21
77	Diagnostic Relevance and Clinical Significance of the New Enhanced Performance M2 (MIT3) ELISA for the Detection of IgA and IgG Antimitochondrial Antibodies in Primary Biliary Cirrhosis. Journal of Clinical Immunology, 2007, 27, 378-387.	2.0	56
78	Anti-mitochondrial antibodies in patients with systemic lupus erythematosus: Revealing the unforeseen. Clinica Chimica Acta, 2006, 373, 183-184.	0.5	17
79	Presence of high avidity anticardiolipin antibodies in patients with autoimmune cholestatic liver diseases. Clinical Immunology, 2006, 119, 203-212.	1.4	53
80	Alterations of leptin during IFN-Î± therapy in patients with chronic viral hepatitis. Journal of Hepatology, 2006, 44, 848-855.	1.8	24
81	Self-mimicking autoimmune domains of hepatitis C virus core antigen. Vaccine, 2006, 24, 6173-6174.	1.7	8
82	Lack of association between appendectomy and primary biliary cirrhosis. Scandinavian Journal of Gastroenterology, 2006, 41, 573-576.	0.6	5
83	Reversion of severe hepatopulmonary syndrome in a non cirrhotic patient after corticosteroid treatment for granulomatous hepatitis: A case report and review of the literature. World Journal of Gastroenterology, 2006, 12, 336.	1.4	9
84	Diagnostic Discordance for Hepatitis C Virus Infection in Hemodialysis: Correlations with Clinical and Laboratory Features. American Journal of Kidney Diseases, 2005, 46, 992-993.	2.1	1
85	Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its Lactobacillus mimic. Hepatology, 2005, 42, 458-465.	3.6	116
86	Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: Antiviral and immunological activity. Hepatology, 2005, 42, 1028-1036.	3.6	90
87	Markers of cell activation and apoptosis in bone marrow mononuclear cells of patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. Journal of Hepatology, 2005, 42, 393-399.	1.8	38
88	Prevalence and clinical significance of anticardiolipin antibodies in patients with type 1 autoimmune hepatitis. Journal of Autoimmunity, 2005, 24, 251-260.	3.0	49
89	Autoimmune hepatitis type 1 and primary biliary cirrhosis have distinct bone marrow cytokine production. Journal of Autoimmunity, 2005, 25, 283-288.	3.0	29
90	HCV-RNA qualitative assay based on transcription mediated amplification improves the detection of hepatitis C virus infection in patients on hemodialysis: Results from five hemodialysis units in central Greece. Journal of Clinical Virology, 2005, 34, 81-85.	1.6	45

#	Article	IF	Citations
91	Blocking of interleukin-10 receptorâ€"a novel approach to stimulate T-helper cell type 1 responses to hepatitis C virus. Clinical Immunology, 2005, 117, 57-64.	1.4	86
92	Single nucleotide polymorphisms in the interferon-gamma and interleukin-10 genes do not influence chronic hepatitis C severity or T-cell reactivity to hepatitis C virus. Liver International, 2004, 24, 90-97.	1.9	22
93	Disease-specific cross-reactivity between mimicking peptides of heat shock protein of mycobacterium gordonae and dominant epitope of E2 subunit of pyruvate dehydrogenase is common in Spanish but not British patients with primary biliary cirrhosis. Journal of Autoimmunity, 2004, 22, 353-362.	3.0	64
94	Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. Journal of Hepatology, 2004, 40, 31-39.	1.8	128
95	Primary biliary cirrhosis presented as peripheral eosinophilia in asymptomatic women with or without elevated alkaline phosphatase. European Journal of Gastroenterology and Hepatology, 2004, 16, 425-428.	0.8	17
96	Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology, 2002, 122, 614-624.	0.6	180
97	Recipient HLA-DR3, tumour necrosis factor-Î± promoter allele-2 (tumour necrosis factor-2) and cytomegalovirus infection are inter-related risk factors for chronic rejection of liver grafts. Journal of Hepatology, 2001, 34, 711-715.	1.8	30